DiaSorin

Historical price data

DiaSorin's mission is to improve healthcare through a broad portfolio of high-quality, specialized immunodiagnostic solutions. A key achievement was the transformative $1.8 billion acquisition of Luminex in 2021, which expanded its technological capabilities into molecular diagnostics and significantly strengthened its North American presence. The company's strategy rests on three pillars: continuous innovation of its proprietary LIAISON® platform, strategic M&A to broaden its test menu and geographic reach, and direct commercial engagement in key markets to drive its razor-and-blade business model.

DiaSorin's core technology is proprietary Chemiluminescence Immunoassay (CLIA), commercialized as the LIAISON® family of automated analyzers. This is complemented by the Luminex-derived xMAP® bead-based multiplexing and molecular diagnostics platforms for multi-analyte and syndromic testing.